Natriumvalproaat Chrono Cf (Valproic Acid, Sodium Valproate)

Valproic acid increases brain levels of the inhibitory neurotransmitter GABA by inhibiting its breakdown and enhancing its synthesis. It also blocks voltage‑gated sodium channels, reducing high‑frequency neuronal firing. Together, these actions calm excessive electrical activity that underlies seizures, mood swings, and migraine triggers.

The dosage of Natriumvalproaat Chrono Cf is individualized by the prescribing clinician based on the patient’s age, weight, indication, and response to therapy. Physicians determine the appropriate starting dose and titration schedule, and patients should follow the prescriber’s instructions exactly.

Valproic acid is classified as Pregnancy Category X because it carries a high risk of birth defects and developmental disorders. It is contraindicated in pregnancy. Limited data exist for breastfeeding, and the drug is generally not recommended for nursing mothers unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other anticonvulsants, valproic acid offers broad-spectrum seizure control and mood‑stabilising properties, but it has a higher risk of hepatotoxicity and teratogenicity. Alternatives such as lamotrigine or carbamazepine may have different efficacy profiles and safety considerations, so choice depends on individual patient factors.

Store Natriumvalproaat Chrono Cf at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, heat, and direct sunlight to maintain stability and potency.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact dosing schedule and whether it is taken once or multiple times daily are determined by the prescriber.

Serious risks include liver failure, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, thrombocytopenia, hyperammonemia, and increased suicidal thoughts. Patients should be monitored regularly for signs of these conditions and seek immediate medical attention if they occur.

Valproic acid is contraindicated in pregnant women, individuals with known hypersensitivity to valproate, patients with severe liver disease, and those with mitochondrial disorders such as POLG‑related disease. It should also be used with caution in patients with a history of pancreatitis or blood dyscrasias.